Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) shares rose 0.3% on Wednesday . The stock traded as high as $6.72 and last traded at $6.49. Approximately 6,993,546 shares changed hands during trading, a decline of 73% from the average daily volume of 25,691,047 shares. The stock had previously closed at $6.47.
Wall Street Analysts Forecast Growth
RXRX has been the subject of a number of recent research reports. KeyCorp dropped their price objective on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating for the company in a research note on Wednesday, January 8th. Cowen reissued a "hold" rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Leerink Partners dropped their price objective on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a research note on Friday, February 28th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a research note on Thursday, February 6th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $8.25.
View Our Latest Stock Report on RXRX
Recursion Pharmaceuticals Stock Up 5.6 %
The company's fifty day moving average price is $7.64 and its 200-day moving average price is $7.07. The stock has a market cap of $2.57 billion, a P/E ratio of -4.31 and a beta of 0.85. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its earnings results on Friday, February 28th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.17). The firm had revenue of $4.60 million during the quarter, compared to the consensus estimate of $19.04 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. Recursion Pharmaceuticals's revenue was down 57.8% compared to the same quarter last year. During the same quarter last year, the business posted ($0.42) EPS. Equities analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.
Institutional Investors Weigh In On Recursion Pharmaceuticals
Several institutional investors have recently made changes to their positions in RXRX. Decker Retirement Planning Inc. bought a new stake in shares of Recursion Pharmaceuticals in the 4th quarter worth about $26,000. Private Trust Co. NA bought a new stake in Recursion Pharmaceuticals during the 4th quarter valued at about $27,000. GAMMA Investing LLC lifted its holdings in Recursion Pharmaceuticals by 1,979.2% during the 4th quarter. GAMMA Investing LLC now owns 5,198 shares of the company's stock valued at $35,000 after buying an additional 4,948 shares in the last quarter. Farther Finance Advisors LLC lifted its holdings in Recursion Pharmaceuticals by 176.9% during the 3rd quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company's stock valued at $42,000 after buying an additional 4,091 shares in the last quarter. Finally, KBC Group NV lifted its holdings in Recursion Pharmaceuticals by 79.9% during the 3rd quarter. KBC Group NV now owns 7,602 shares of the company's stock valued at $50,000 after buying an additional 3,377 shares in the last quarter. Institutional investors own 89.06% of the company's stock.
About Recursion Pharmaceuticals
(
Get Free Report)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Further Reading
Before you consider Recursion Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.
While Recursion Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
